**Pharmaceutical Products:** 70%
**Biotechnology:** 20%
**Healthcare Services:** 10%

**TOP 3 Markets:**
1. **China:** 60%
2. **Southeast Asia:** 20%
3. **Europe:** 10%

China Resources Double-Crane Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by biotechnology and healthcare services. The largest market is China itself, attributed to the strong local presence and trust in domestic brands.

Southeast Asia and Europe are also significant markets, with the company benefiting from the increasing demand for pharmaceutical products in these regions. Expansion into these markets is supported by strategic partnerships and adaptation to local needs.

**Production Sites:** Mainly in China

China Resources Double-Crane Pharmaceutical Co., Ltd. primarily produces its products in China. The company has several production facilities in the country, strategically located to maximize supply chain efficiency and meet demand in the domestic market. These sites are equipped with modern technologies to meet the high quality standards of the pharmaceutical industry.

Additionally, the company may have expanded its production capacities in recent years to respond to the increasing demand both domestically and internationally. It is common for large pharmaceutical companies like China Resources Double-Crane to also invest in research and development to continuously improve their production processes.

**Focus on Research and Development:** Increase in R&D budget by 20% (2025)

**International Expansion:** Entry into new markets in Southeast Asia and Africa (2024-2026)

**Product Diversification:** Introduction of five new lines of medications (2025)

China Resources Double-Crane Pharmaceutical Co., Ltd. is pursuing a growth strategy that heavily emphasizes increasing investments in research and development. The company plans to increase its R&D budget by 20% to develop innovative medications and expand its product pipeline.

Additionally, the company is focusing on international expansion, particularly in emerging markets in Southeast Asia and Africa, to strengthen its market presence and tap into new revenue sources.

Another key component of the growth strategy is diversifying the product portfolio. By 2025, the company plans to introduce five new lines of medications to meet the changing needs in the healthcare sector and enhance its competitiveness.

**Main imported raw materials:** Active ingredients, pharmaceutical intermediates, packaging materials

**Countries of origin:** India, Germany, USA

China Resources Double-Crane Pharmaceutical Co., Ltd. mainly imports active ingredients and pharmaceutical intermediates needed for the production of their medicines. India is one of the largest suppliers of pharmaceutical active ingredients worldwide and therefore a significant trading partner for the company.

In addition, the company sources special pharmaceutical intermediates and packaging materials from Germany and the USA, which are crucial for the quality and safety of their products. These countries are known for their high standards in pharmaceutical production and offer materials that meet international quality requirements.

**Market share:** 5% in the Chinese pharmaceutical market (estimated 2026)
**Research & Development (R&D) expenses:** 8% of revenue (2025)
**Industry comparison R&D:** Average of 6% of revenue

China Resources Double-Crane Pharmaceutical Co., Ltd. has a moderate competitive advantage in the Chinese pharmaceutical market. The company benefits from an established brand name and a diversified product portfolio that includes both generic and innovative drugs.

A significant advantage is the above-average investment in research and development, which enables the company to develop new products and improve existing ones. This strengthens its competitive position compared to other market participants who, on average, invest less in R&D.

Additionally, the company benefits from the support of the China Resources Group, providing access to extensive resources and networks. However, it operates in a fiercely competitive market where both local and international companies are active, which mitigates the competitive advantage.

**Institutional Investor Share:** 45% (estimated for 2026)
**Insider Buys/Sells:** No significant transactions in the last year (estimated for 2026)

The institutional investor share in China Resources Double-Crane Pharmaceutical Co., Ltd. is estimated to be around 45%. This demonstrates the confidence of institutional investors in the company's long-term stability and growth potential.

In 2026, there were no significant insider buys or sells, indicating that the management may be satisfied with the current company strategy and valuation. Such transactions are often seen as indicators of management's assessment of the company's future development.

**Market share of China Resources Double-Crane Pharmaceutical Co., Ltd.:** Estimate: 5-7% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15-18%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10-12%
3. **CSPC Pharmaceutical Group Limited:** 8-10%
4. **Jiangsu Hengrui Medicine Co., Ltd.:** 7-9%
5. **China Resources Double-Crane Pharmaceutical Co., Ltd.:** 5-7%
6. **Huadong Medicine Co., Ltd.:** 4-6%
7. **Sino Biopharmaceutical Limited:** 3-5%
8. **Yunnan Baiyao Group Co., Ltd.:** 3-5%
9. **Tasly Pharmaceutical Group Co., Ltd.:** 2-4%
10. **Tong Ren Tang Technologies Co., Ltd.:** 2-4%

**Moat of China Resources Double-Crane Pharmaceutical Co., Ltd.:**

China Resources Double-Crane Pharmaceutical has a moderate moat, mainly based on its strong brand recognition and established distribution network. The company benefits from the support of its parent company China Resources, providing access to extensive resources and networks.

However, compared to its competitors, the moat is less pronounced. Companies like Sinopharm and Shanghai Pharmaceuticals have a stronger competitive advantage due to their size and broader product range. Particularly, Sinopharm benefits from comprehensive market presence and a leading position in pharmaceutical product distribution in China.

In summary, while China Resources Double-Crane Pharmaceutical has some competitive advantages, they are less significant compared to industry leaders. To strengthen the moat, the company could invest in research and development or form strategic partnerships to enhance its market position.

**Revenue growth:** 8.5% (2025)
**Research and development ratio:** 6.2% of revenue (2025)
**Market share in the Chinese pharmaceutical sector:** 4.5% (2025)

China Resources Double-Crane Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025, indicating solid demand for its products and an effective market strategy. Investments in research and development, accounting for 6.2% of revenue, suggest that the company is striving to expand its product range and develop innovative solutions to remain competitive.

The 4.5% market share in the Chinese pharmaceutical sector indicates that the company holds a significant position in the market, pointing to a stable customer base and a strong brand presence. These factors, combined with a strategic focus on growth areas, could suggest that the stock presents an attractive investment opportunity.

However, potential investors should also consider external factors such as regulatory changes and economic conditions in China that could impact future performance.

**Dividend Yield:** 2.5% (estimated for 2026)

**Dividend History:** Steady payout over the last five years

China Resources Double-Crane Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield of 2.5% for 2026 is based on historical payouts and the current market environment.

The company has proven to be stable in the past, supported by its continuous dividend payments. Therefore, investors can expect a certain level of reliability in the dividend policy, as long as no significant market changes or company-specific issues arise.